Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525495 | 0.79 | CA1 (0.37) | TSHRALDH1A1HPGD | |
| SCHEMBL3287811 | 0.76 | ALDH1A1 (0.37) | LMNATSHRALDH1A1 | |
| SCHEMBL262553 | 0.73 | DDAH1 (0.35) | DDAH1TSHRMAPTHPGDALOX12 | |
| SCHEMBL901650 | 0.72 | — | — | |
| SCHEMBL28728927 | 0.71 | DDAH1 (0.34) | DDAH1TSHRMAPTHPGDALOX12 | |
| SCHEMBL250869 | 0.69 | — | — | |
| SCHEMBL800638 | 0.69 | — | — | |
| SCHEMBL289489 | 0.68 | HDAC1 (0.43) | LMNATSHRALDH1A1MAPK1 | |
| SCHEMBL10455692 | 0.68 | ALDH1A1 (0.37) | DDAH1TSHRALDH1A1MAPTHPGD | |
| SCHEMBL24133771 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926719-B1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | disclosed |
| US-9388175-B2 | 2-aniline-4-aryl substituted thiazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-07-12 | — | — | US | disclosed |
| US-20110269748-A1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-03 | — | — | US | disclosed |
| EP-1926719-A2 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031440-A2 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269748-A1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | CHRNA4, CHRNA5, CHRNA7 | LMNA 1918/4885DDAH1 911/4885TSHR 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.